Clinical Trial Update: Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC [Phase 3]

View source ↗

Summary

Phase III study evaluating two regimens of abiraterone acetate in metastatic castration-resistant prostate cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone Acetate (II) (abiraterone acetate)
• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Ding-Wei Ye | Conditions: Abiraterone Acetate, MCRPC (metastatic Castration-resistant Prostate Cancer) | Phase 3 | Status: NOT_YET_RECRUITING